MYCN and chronic myelogenous leukemia, BCR-ABL1 positive: MYCN can promote proliferation, immortalization, stemness, and carcinogenesis and aggravate imatinib resistance.413 However, the effect of MYCN upregulation on CML resistance has not been fully elucidated.